Compare · NVO vs VINC
NVO vs VINC
Side-by-side comparison of Novo Nordisk A/S (NVO) and Vincerx Pharma Inc. (VINC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and VINC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 1538.8x VINC ($143.2M).
- Over the past year, NVO is down 34.2% and VINC is up 0.0% - VINC leads by 34.2 points.
- NVO has hit the wire 5 times in the past 4 weeks while VINC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for VINC).
- Company
- Novo Nordisk A/S
- Vincerx Pharma Inc.
- Price
- $41.18+6.93%
- $0.10-64.86%
- Market cap
- $220.35B
- $143.2M
- 1M return
- +13.32%
- +0.00%
- 1Y return
- -34.24%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 6
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Vincerx Pharma Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest VINC
- Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.
- SEC Form DEFA14A filed by Vincerx Pharma Inc.
- Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
- SEC Form DEFA14A filed by Vincerx Pharma Inc.
- SEC Form 8-K filed by Vincerx Pharma Inc.
- Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
- SEC Form DEFA14A filed by Vincerx Pharma Inc.
- Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
- SEC Form DEFA14A filed by Vincerx Pharma Inc.
- SEC Form 10-Q filed by Vincerx Pharma Inc.